Chinese SLE Treatment and Research Group (CSTAR) Registry: Prevalence and Risk Factors for Chronic Scarring Alopecia in Patients with Systemic Lupus Erythematosus

August 2020 in “ Research Square (Research Square) ”

Yirong Xiang, Mengtao Li, Hui Luo, Yanhong Wang, Xinwang Duan, Cheng Zhao, Zhan Feng, Zhenbiao Wu, Hongbin Li, Min Yang, Jian Xu, Wei Wei, Lijun Wu, Hanxiao You, Junyan Qian, Xiaoxi Yang, Can Huang, Jiuliang Zhao, Qian Wang, Xiaomei Leng, Xinping Tian, Yan Zhao, Xiaofeng Zeng

chronic scarring alopecia systemic lupus erythematosus mucocutaneous lesions SLICC/ACR-DI scores anti-Sm antibodies immunosuppressants

TLDR Active treatment can help prevent scarring hair loss in SLE patients.

The study investigated the prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus (SLE) using data from the Chinese SLE Treatment and Research Group (CSTAR) registry. Among 4,792 SLE patients, 374 (7.80%) experienced scarring alopecia. Risk factors identified included mucocutaneous lesions, high SLICC/ACR-DI scores, and positive anti-Sm antibodies. Conversely, renal and cardio-respiratory involvements, as well as treatment with immunosuppressants, were found to be protective factors. The study concluded that active treatment strategies should be implemented to prevent the occurrence of scarring alopecia in SLE patients.